MDMA THERAPY

Why some people choose LSD therapy for trauma processing

Psychedelic therapy has been receiving increasing attention in recent years, including among people seeking new ways to cope with trauma. In that search, the same question often recurs: if psilocybin (truffles or magic mushrooms) is so extensively researched, why do some people still opt for LSD therapy?

It is important to immediately add a nuance: the scientific basis for psilocybin is currently broader than that for LSD, partly because more clinical studies have been conducted. This does not automatically mean that LSD is “better” or “worse,” but it does mean that statements regarding effectiveness must be formulated cautiously. Additionally, availability varies by country and context. In practice, psychedelic sessions are often discussed and structured within guided programs focused on safety, preparation, setting, and integration, rather than as a quick fix.

In this article, we explain why some people consider LSD therapy for trauma processing, what differences are often cited between LSD and psilocybin, and what important points to consider regarding safety and harm reduction. Where relevant, we distinguish between scientific research, personal accounts, and practical considerations.

Trauma, therapy, and why people look off the beaten path

Trauma is a broad concept. It can involve one-off, significant events, but also prolonged stress, insecurity, or developmental trauma. Many people experience symptoms such as flashbacks, avoidance, sadness, irritability, shame, numbness, or difficulty with closeness and trust. Not everyone identifies with the same words, and not everyone fits into a diagnostic category.

When conventional forms of therapy prove insufficient or reach a dead end, people may start looking for alternatives. Psychedelic therapy is then sometimes seen as a possible route to break patterns or allow emotions to surface. At the same time, it is important to remain realistic: psychedelics are no guarantee of a breakthrough and can also trigger difficult experiences. The effect depends strongly on preparation, context, guidance, and subsequent integration.

What exactly is LSD therapy (and what is meant by it)?

People mean different things by “LSD therapy.” In the literature, it often refers to historical forms of therapy from the last century, and to newer research interventions in a controlled setting. In practice, the term is also used for guided sessions in which LSD is employed with a therapeutic intention, including preparation and integration.

Please note: psychedelic sessions involving substances such as LSD do not take place in a medical or clinical setting everywhere. Legal and practical frameworks vary by country and change over time. On mdmatherapie.nl, we discuss this topic primarily from an informative perspective and from a harm reduction point of view: how people can understand and minimize risks, and what questions to ask regarding guidance, screening, setting, and aftercare.

Why psilocybin has been studied more often than LSD

A frequently cited reason that psilocybin is receiving more scientific attention is that studies are logistically simpler with it. Psilocybin generally has a shorter duration than LSD. A shorter session duration makes it easier to plan research, deploy supervisors, and control costs. That is a practical factor that is separate from the question of what is “deeper” or “more effective” for an individual.

In addition, the modern line of research regarding psilocybin has been established for a longer period and is more consistent. As a result, the amount of clinical data is greater, and protocols have been repeated more frequently. For LSD, renewed research interest is smaller and less widespread, meaning there is simply less recent data to base firm conclusions on.

That means: if someone says “psilocybin is proven and LSD is not,” that is often a simplistic view. It is more accurate to say: there is currently more research available for psilocybin, and the modern evidence base for LSD is more limited.

The nature of the experience: emotional versus cognitive (as an experiential framework)

In anecdotal accounts, psilocybin is often described as more emotional, inward-focused, and connected to feelings, memories, and existential themes. People sometimes describe being led, as it were, “to the core” of a theme, including sadness, grief, or old wounds. This can sound appealing for trauma processing, as emotional access and self-compassion can be important elements in recovery processes.

In anecdotal evidence, LSD is actually relatively often described as clearer, more analytical, and cognitively activating. Some people experience a greater capacity to examine thought patterns, question beliefs, and see connections. This may be consistent with people who are very much in their heads, struggle with maintaining an overview, or who specifically want to take steps through insight and reflection. However, it is not a hard and fast rule. An LSD experience can also be emotionally intense, and psilocybin can likewise provide sharp cognitive insights.

This “emotional versus cognitive” classification is therefore primarily a simplified experiential framework. It is not a hard and fast rule, nor is it a reliable predictor of individual outcomes. Set (mental state), setting (environment), dose, sleep, stress, expectations, and previous experiences have a major influence.

Why the longer duration of LSD is sometimes seen as an advantage

A clear practical difference is the duration. LSD can have a long-lasting effect, often 8 hours or longer, and some sessions, including aftercare, last even longer. For some people, that is precisely the reason to consider LSD: there is more time to let a process unfold, to approach multiple “layers” of a theme, and to work with insights while the experience is still ongoing.

In trauma processing, time can be an ambiguous concept. On the one hand, it can be helpful not to have to rush and to calmly process difficult moments with support. On the other hand, a long duration can also be burdensome, especially if someone becomes anxious, overstimulated, or struggles with a loss of control. What provides space for one person may be too intense or too exhausting for another.

Therefore, the question is not only “what works better,” but also: what suits an individual’s resilience, recovery pace, sensitivity to stimuli, and the quality of guidance and integration?

Not everyone reacts the same way: variation and uncertainty

An important nuance that recurs in both practice and research is individual variation. People differ in temperament, trauma history, coping style, neurobiology, medication use, physical health, and expectations. Two people with similar symptoms can still react very differently to the same substance and the same setting.

This makes it difficult to make general statements such as “LSD is better for trauma” or “psilocybin is always deeper.” At this moment, it is fairer to say: there are patterns in how people describe experiences, but their predictive value is limited. Anyone considering a choice would do well not to rely solely on anecdotes, but also to look at safety frameworks, screening, and whether there is a solid plan for integration.

Harm reduction: safety, setting, guidance and integration

When people consider psychedelics in relation to trauma, safety is a core topic. Harm reduction does not mean that risks disappear, but rather that you take them seriously and reduce them where possible. Some frequently recurring points of attention include:

First: preparation. Clear intentions can help, but rigid expectations can actually create tension. It is often useful to discuss in advance which topics are sensitive, which signals indicate overload, and what support someone needs if anxiety or flashbacks arise.

Secondly: screening and contraindications. Some psychological vulnerabilities (such as a history of psychosis or mania) are considered important risk factors in many protocols. Medication and physical factors may also be relevant. This article does not provide individual medical advice, but it does emphasize that a thorough intake is essential.

Thirdly: setting and guidance. A calm, safe environment, clear agreements, and a facilitator experienced in crisis skills and trauma-sensitive work can make a big difference. Especially with LSD, the long duration is a factor: is there sufficient guidance for the entire session, including the “processing” and the fatigue afterward?

Fourth: integration. Insights gained during a session are not automatically lasting changes. Integration is about translating experience into daily life, step by step. This can consist of conversation, journaling, body-oriented exercises, rest, learning to feel boundaries, and sometimes also adjusting relationships or workload. Without integration, an experience can remain confusing or even be disruptive.

How people choose between psilocybin and LSD in practice

In real-life stories, you frequently hear that people work with psilocybin first, precisely because the process is more manageable in duration and because there are more shared protocols and references. If someone subsequently has a specific reason to explore a longer, more reflective or analytical experience, LSD may be considered.

That order is not a fixed rule, nor is it a recommendation for everyone. It primarily shows that choices are often both pragmatic and personal: what suits someone's intentions, capacity, time, guidance, and need for structure?

Anyone who wants to read more about the background of this question can also view the forum answer that summarizes and nuances this discussion: https://trip-forum.nl/qa/waarom-kiezen-mensen-voor-lsd-therapie/. Please note that this type of source primarily has an informative and experience-based approach and does not equate to clinical evidence.

Where MDMA does and does not fit into this conversation

Because many people seeking trauma processing also encounter MDMA, it is useful to make one distinction explicit. MDMA is being investigated in scientific research in combination with therapy, including for PTSD, but conclusions regarding effectiveness and availability depend on studies, regulations, and professional frameworks. Currently, MDMA sessions can only be discussed within scientific research or in practice via harm reduction. This means that the emphasis lies on information, safety, and limiting risks, not on medical treatment or cure claims.

Anyone considering supervised sessions would do well to ask transparently about the working method, screening, emergency plan, integration, and boundaries. If you wish to explore in detail whether an MDMA session in a supervised setting might be suitable as part of a broader process, you can register via https://mdmatherapie.nl/aanmelden-mdma-sessie/. View this as a starting point for information and alignment, not as a promise of an outcome.

Conclusion

Some people choose LSD therapy for trauma processing because the experience in anecdotal accounts is more often described as clear, analytical, and prolonged, with ample room for self-reflection and pattern analysis. Psilocybin currently has a broader scientific basis and is often viewed as emotionally deeper and more inwardly focused, but individual reactions vary widely and predictability is limited.

Regardless of which route someone explores, safety, screening, setting, and integration remain decisive. Psychedelic experiences can be valuable, but require nuance and careful consideration, especially in relation to trauma.